According to a recent press release by the Food and Drug Administration (FDA), Darvon and Darvocet, the popular prescription pain medications manufactured by Xanodyne Pharmaceuticals, Inc., were withdrawn from the market on November 19, 2010 as part of an FDA recall.
Darvon and Darvocet are brand versions of the opioid Propoxyphene, which was first approved for use by the FDA in 1957. Propoxyphene is known as Darvon when sold alone and Darvocet when sold in combination with acetaminophen.
The withdrawal of these drugs from the market came in response to the FDA’s determination that the risk of developing extreme or possibly fatal heart rhythm abnormalities outweighed the drugs’ potential benefits. These potential health problems became apparent after the FDA conducted studies involving healthy people taking normal amounts of the drugs and found that some of those people developed heart side effects.
This drug recall is significant, as it will affect an estimated ten million Americans who are currently on the medication. In 2004 alone, approximately 23 million prescriptions were filled for Propoxyphene, making it the 12th most frequently prescribed generic drug in the U.S.
Patients who are taking Darvon, Darvocet, or other Propoxyphene-based medications should contact their physicians to find an alternative pain medication, as doctors have been instructed to stop prescribing these drugs as part of the FDA recall. If you or a loved one have suffered health problems after using Darvon or Darvocet, contact a Chicago personal injury lawyer at GWC Injury Lawyers.
When considering whether to file a Darvon lawsuit or a Darvocet lawsuit, it is important to consult with a personal injury firm that is experienced in pharmaceutical litigation. With our talented team of experienced trial attorneys and with the resources necessary to successfully litigate complex cases like these, contact the Chicago Darvocet recall law firm of GWC Injury Lawyers to make sure you get the best representation.
Call us at 1-312-464-1234 for a free, no-obligation consultation.